UCB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 124.6 EUR | +0.65% |
|
+2.76% | +57.86% |
| 04-11 | Berenberg Reiterates UCB's Purchase Rating, Raises PT | MT |
| 04-11 | UCB : Berenberg, Buy, raises its price target | CF |
| Sales 2024 * | 5.62B 6B 481B | Sales 2025 * | 6.31B 6.75B 541B | Capitalization | 23.63B 25.27B 2,024B |
|---|---|---|---|---|---|
| Net income 2024 * | 466M 498M 39.9B | Net income 2025 * | 880M 941M 75.35B | EV / Sales 2024 * | 4.5 x |
| Net Debt 2024 * | 1.63B 1.74B 139B | Net Debt 2025 * | 802M 857M 68.63B | EV / Sales 2025 * | 3.87 x |
| P/E ratio 2024 * |
50.8
x | P/E ratio 2025 * |
25.8
x | Employees | 8,767 |
| Yield 2024 * |
1.12% | Yield 2025 * |
1.17% | Free-Float | 61.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on UCB
More press releases
| 1 day | +0.65% | ||
| 1 week | +2.76% | ||
| Current month | +8.87% | ||
| 1 month | +8.78% | ||
| 3 months | +42.67% | ||
| 6 months | +77.93% | ||
| Current year | +57.86% |
1 week
120.40
125.20
1 month
112.65125.20
Current year
78.72125.20
1 year
65.40125.20
3 years
65.40125.20
5 years
60.18125.20
10 years
54.84125.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 31/05/11 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 57 | 30/06/20 |
| Chief Tech/Sci/R&D Officer | 63 | 30/09/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | 27/04/16 | |
Dame Davies
BRD | Director/Board Member | 73 | 31/12/13 |
| Chief Executive Officer | 65 | 31/05/11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.88% | 2 M€ | +7.72% | ||
| 0.72% | 14 M€ | +5.66% | - | |
| 0.72% | 5 M€ | +10.09% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 124.6 | -0.44% | 371,409 |
| 25/04/24 | 125.1 | +3.56% | 349,967 |
| 24/04/24 | 120.8 | -0.78% | 179,471 |
| 23/04/24 | 121.8 | -0.20% | 184,505 |
| 22/04/24 | 122 | +0.66% | 311,888 |
Real-time Euronext Bruxelles, April 26, 2024 at 04:35 pm
More quotes
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Sector
Pharmaceuticals
Calendar
25/07/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
124.6
EUR
Average target price
123.2
EUR
Spread / Average Target
-1.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +57.86% | 25.23B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B | |
| +2.29% | 7.72B |
- Stock Market
- Equities
- UCB Stock
